Market Size of Global Chlamydia Infection Diagnostics Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 8.50 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Chlamydia Infection Diagnostics Market Analysis
The chlamydia infection diagnostics market is expected to register a CAGR of 8.5% over the forecast period.
COVID-19 had a significant impact on market growth while it lasted. As per a report published by the Centers for Disease Control and Prevention (CDC) in April 2022, the decline in reported chlamydia was likely due to the decreased sexually transmitted diseases screening and underdiagnosis during the pandemic rather than a reduction in new infections. This also contributed to an overall decrease in the number of reported Sexually Transmitted infections in 2020 (from 2.5 million reported cases in 2019 to 2.4 million in 2020). According to the WHO, in 2022, it was stated that during the COVID-19 pandemic, many countries had reported low coverage for preventive testing and treatments related to sexually transmitted infections. Hence this has led to a resurgence of STIs and the emergence of non-classical STIs globally. This will elevate the market's growth over the forecast.
The chlamydia infection diagnostics market is growing due to the increasing prevalence rates of chlamydia and the growing demand for rapid testing. Owing to the rising prevalence of chlamydia and the significant shift from conventional technologies to molecular diagnostics, the market studied is growing rapidly. For instance, according to the CDC in 2021, a total of 1,628,379 cases of chlamydia trachomatis infection were reported, making it the most common notifiable condition in the United States that year. This case count corresponds to a rate of 552.8 cases per 100,000 population, an increase of 2.8% compared with the past years. The growing rates of this disease are expected to increase the diagnostics and also the need for developing more advanced tests, which is expected to increase the growth of the market during the forecast period.
Additionally, government initiatives are expected to drive the growth of the studied market. For Instance, in June 2021, the government of the United Kingdom mentioned that the National Chlamydia Screening Programme (NCSP) will focus testing on women, who are at the highest risk of serious consequences from the infection. The program aims to provide treatment more rapidly and expand testing in community settings for sexually active women aged under 25 years. Such initiatives by various governments in reducing the burden of diseases are increasing market growth. However, people are more conscious about their privacy and social status, when it comes to STD testing, which is limiting the growth of the market studied.
Chlamydia Infection Diagnostics Industry Segmentation
As per the scope of the report, chlamydia is a curable and common sexually transmitted infection that may not cause symptoms. It spreads through vaginal, anal, and oral sex. The infection is carried in semen (cum), pre-cum, and vaginal fluids. Chlamydia can infect the penis, vagina, cervix, anus, urethra, eyes, and throat. It affects people of all ages but is most common in young women.
The Chlamydia Infection Diagnostics Market is Segmented by Type (Culture Tests, Nucleic Acid Amplification Test (NAAT), Direct Fluorescent Antibody Test, Serology Tests, and Others), End-User (Hospitals, Diagnostic Centers and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Test Type | |
| Culture Tests | |
| Nucleic Acid Amplification Test (NAAT) | |
| Direct Fluorescent Antibody Test | |
| Serology Tests | |
| Other Test Types |
| By End User | |
| Hospitals | |
| Diagnostic Centers | |
| Other End Users |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Global Chlamydia Infection Diagnostics Market Size Summary
The chlamydia infection treatment market is experiencing significant growth, driven by the increasing prevalence of chlamydia and the demand for rapid testing solutions. The shift from conventional diagnostic methods to advanced molecular diagnostics, such as Nucleic Acid Amplification Tests (NAAT), is a key factor propelling market expansion. These tests offer higher sensitivity and specificity, facilitating more accurate diagnoses without the need for invasive procedures. Government initiatives, like the UK's National Chlamydia Screening Programme, aim to enhance testing and treatment accessibility, particularly for high-risk populations, further contributing to market growth. However, societal concerns regarding privacy and stigma associated with STD testing pose challenges to market expansion.
The market is characterized by a fragmented landscape with numerous global and regional players, including Abbott Laboratories, Becton, Dickinson and Company, and Hologic, Inc. Recent product approvals, such as the FDA's clearance of the Binx Health IO CT assay and Abbott's Alinity m STI assay, are expected to bolster market growth by increasing awareness and availability of chlamydia diagnostics. North America holds a leading position in the market, supported by high infection rates and ongoing product innovations. Collaborative efforts, like those between Chiricahua Community Health Centers and Visby Medical, aim to improve STI diagnosis and treatment, highlighting the dynamic nature of the market.
Global Chlamydia Infection Diagnostics Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Prevalence Rate of Chlamydia Infection
-
1.2.2 Increasing Initiatives for Chlamydia Testing and Product Innovation
-
-
1.3 Market Restraints
-
1.3.1 Social Stigma Associated with Patients Visiting Specialized STD Clinics
-
1.3.2 Huge Proportion of Patients Infected with Chlamydia in Out-of-reach Geographic Areas
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD million)
-
2.1 By Test Type
-
2.1.1 Culture Tests
-
2.1.2 Nucleic Acid Amplification Test (NAAT)
-
2.1.3 Direct Fluorescent Antibody Test
-
2.1.4 Serology Tests
-
2.1.5 Other Test Types
-
-
2.2 By End User
-
2.2.1 Hospitals
-
2.2.2 Diagnostic Centers
-
2.2.3 Other End Users
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Global Chlamydia Infection Diagnostics Market Size FAQs
What is the current Global Chlamydia Infection Diagnostics Market size?
The Global Chlamydia Infection Diagnostics Market is projected to register a CAGR of 8.5% during the forecast period (2024-2029)
Who are the key players in Global Chlamydia Infection Diagnostics Market?
Abbott Laboratories, F. Hoffmann-La Roche Ltd, Hologic, Inc., Quidel Corporation and DiaSorin SpA are the major companies operating in the Global Chlamydia Infection Diagnostics Market.
